LL-37
37-amino acid human cathelicidin antimicrobial peptide. The only cathelicidin found in humans. Disrupts bacterial membranes via electrostatic interaction with lipid bilayers. Also modulates innate immune response — recruits immune cells, promotes angiogenesis, and has anti-biofilm activity. Active against bacteria, fungi, and some viruses.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- wbc
- hs-crp
- pregnancy
- autoimmune-disease
- PMID:16278835Antimicrobial peptides and the innate immune response — Peptides, 2006
- PMID:22110885LL-37, the only human member of the cathelicidin family of antimicrobial peptides — Biochim Biophys Acta, 2012
LL-37 is your body's endogenous antibiotic. It punches holes in bacterial membranes. It disrupts biofilms — the slime-fortress structures that make chronic infections resistant to conventional antibiotics. The anti-biofilm property is the most interesting clinical angle. Chronic sinusitis, SIBO, persistent Lyme — conditions where biofilm formation is the therapeutic bottleneck. The evidence for exogenous LL-37 injection in these contexts is preclinical. The mechanism is sound. The clinical data is not there yet.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See LL-37 in a protocol matched to you